ArticleEJHaem2025
Management of Short Saphenous Vein Thrombosis Close to the Saphenopopliteal Junction: A Survey of the Membership of HaemSTAR, British Society for Haemostasis and Thrombosis and VTE Exemplar Centres in the United Kingdom.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The optimal management of superficial thrombophlebitis (STP) close to the saphenopopliteal junction (SPJ) is not known. Methods: We conducted an online survey of members of the HaemSTAR network, British society of haemostasis and thrombosis and UK VTE exemplar network over a 6-week period. Results: Fifty-three respondents participated in the survey (estimated 22% response rate). Note that 89% of respondents indicated they would manage all STP at the SPJ with anticoagulation, with 70% indicating they would offer 3 months of therapeutic anticoagulation. The most common threshold for instigating anticoagulation was being within 3 cm off the SPJ (68%). Factors most associated with the decision to anticoagulate included previous thrombosis, active malignancy, persistent immobilisation and severe symptoms (with hospitalisation, hyperestrogenaemic states, thrombophilia and recent surgery being additionally identified in the non-treatment group). Conclusion: Despite lack of evidence, most UK practitioners surveyed offered intermediate to treatment doses of anticoagulation in the case of STP within 3 cm of the SPJ. Further research is needed to assess the validity of this approach. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.